Retatrutide
An investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, demonstrating weight reduction of up to 24.2% in phase 2 trials alongside improvements in cardiometabolic parameters and hepatic steatosis. All presented information is based on scientific publications which can be found at the end of product description below.
Product Specifications
Description
All presented information is based on scientific publications which can be found at the end of product description below.
Retatrutide (LY3437943) is a synthetic triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly, enabling simultaneous modulation of appetite, glycemic control, energy expenditure, and lipid metabolism.
Research Highlights
1. Obesity β Phase 2 trials showed 22.8-24.2% weight reduction at 8-12mg doses over 48 weeks, comparable to bariatric surgery. Liver fat reduced by up to 82.4%.
2. Type 2 Diabetes β HbA1c reduction of 2.16% at 12mg (vs 0.43% placebo). Weight loss of 16.94% with continued trend beyond 36 weeks.
3. Liver Protection β 89-93% of patients achieved hepatic fat normalization at 48 weeks, positioning retatrutide as promising for metabolic liver disease.
References available upon request.
The product is intended for scientific research and development purposes only. Chemical substances shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. Intended only for in-vitro research, such as Receptor-ligand binding studies, Enzyme activity assays, Cell proliferation assays, Cell signaling assays, Epitope mapping, etc.
Research Use Only: The product is intended for scientific research and development purposes only. Chemical substances shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. Intended only for in-vitro research, such as Receptor-ligand binding studies, Enzyme activity assays, Cell proliferation assays, Cell signaling assays, Epitope mapping, etc.
πͺπΊ EU & UK Shipped β’ Free over β¬300 β’ 2-5 Business Days
Frequently asked questions
- Retatrutide is a synthetic 39-amino-acid peptide engineered as a triple agonist of GLP-1, GIP, and glucagon receptors. Molecular weight β 4731 Da. It is one of the most studied next-generation GLP-1 class molecules in current clinical research (under the trade name LY3437943 in active Eli Lilly trials).
- Each batch is HPLC-MS verified at β₯98% purity (39-residue peptides reach this ceiling reliably). The COA includes the chromatogram, MS trace, and synthesis details.
- Store lyophilised at -20 Β°C in a sealed, desiccant-protected vial. Once reconstituted, retatrutide is best aliquoted and stored frozen for stability β large peptides are particularly sensitive to freeze-thaw and surface adsorption.
- Retatrutide is being investigated in clinical trials for obesity and metabolic disease (Phase III as of 2025-2026). Research-grade material is used in preclinical pharmacology, receptor binding studies, and metabolic models. It is an investigational drug, not an approved medication.
- Retatrutide is currently an investigational drug in clinical trials. It is NOT approved by FDA, EMA, or any other regulator for any indication as of 2026. Supplied strictly for laboratory research β not for human or veterinary use.
